Protocol Ledger

NCT06475781 · Phase II · RECRUITING

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)

Interventional Phase II clinical trial protocol NCT06475781 sponsored by Foresee Pharmaceuticals Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-01 Enrollment: 126 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06475781
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)126 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06475781
Protocol FieldVerified Registry Value
NCT IdentifierNCT06475781
Consolidated Lead SponsorForesee Pharmaceuticals Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment126 participants (ESTIMATED)
Registered Start Date2025-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI